BioSpace News Archive

Drug Development

Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis

Over 71% of Patients Treated with ILUMYA™ Achieved ACR20 Response After 24 Weeks, with Significant Improvement as Early as 8 Weeks MUMB

June 14, 2019
·
10 min read
Biotech Bay

Study Demonstrates Smokers Who Used Non-Tobacco-Flavored JUUL Products Were More Likely To Switch From Cigarettes Than Those Who Used Tobacco-Flavored JUUL Products

Poster presented at 6th Global Forum on Nicotine, Warsaw, Poland

June 14, 2019
·
3 min read
Drug Development

ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting

ArQule, Inc. announced preliminary results from the Company’s phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase in patients with relapsed or refractory hematologic malignancies at the 2019 European Hematology Association Annual Meeting in Amsterdam, the Netherlands.

June 14, 2019
·
8 min read
Drug Development

New Data Presented at 24th EHA Congress From Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

Oncopeptides AB, announced new data presented at the 24th Congress of the European Hematology Association in Amsterdam, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1 study.

June 14, 2019
·
8 min read
Business

OneFifteen Opens the First of its State-of-the-Art Facilities for the Treatment of Opioid Use Disorder in Dayton, Ohio

OneFifteen, a non-profit ecosystem dedicated to the full and sustained recovery of people living with opioid addiction, is celebrating the opening of the first facilities within its state-of-the-art campus in Dayton, Ohio.

June 14, 2019
·
6 min read
Drug Development

bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress

bluebird bio, Inc. announced updated results from the completed Phase 1/2 Northstar study, and new data from the Phase 3 Northstar-2 and Phase 3 Northstar-3 clinical studies of its LentiGlobin® gene therapy for patients with transfusion-dependent β-thalassemia, at the 24th European Hematology Association Congress in Amsterdam, the Netherlands.

June 14, 2019
·
10 min read
Drug Development

Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in its Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus (RSV)

EDP-938 achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo

June 14, 2019
·
7 min read
Drug Development

Positive Phase 3 Extension Data for ULTOMIRIS® (ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at European Hematology Association (EHA) Congress

ULTOMIRIS demonstrated consistent efficacy and safety through 52 weeks, with no cases of breakthrough hemolysis (BTH) associated with incomplete C5 complement inhibition

June 14, 2019
·
28 min read
Business

Khiron Announces Changes to Leadership Team with Appointment of Wendy Kaufman as CFO

Khiron Life Sciences Corp., a cannabis company with core operations in Latin America, announced the appointment of Wendy Kaufman as CFO, effective July 2, 2019.

June 14, 2019
·
3 min read
Deals

Bruker to Host Investor Day on June 20th, 2019

Bruker Corporation will host an Investor Day on June 20th, 2019, starting at 8:00 AM Eastern Time, at the Nasdaq MarketSite, 4 Times Square in New York City.

June 14, 2019
·
1 min read